Cellectis (NASDAQ:CLLS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.
According to Zacks, “Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France. “
A number of other analysts also recently weighed in on CLLS. Jefferies Group reissued a “buy” rating and set a $47.00 target price on shares of Cellectis in a research report on Sunday, October 29th. ValuEngine downgraded shares of Cellectis from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Oppenheimer reissued an “outperform” rating and set a $40.00 target price on shares of Cellectis in a research report on Thursday, December 28th. Finally, BidaskClub raised shares of Cellectis from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Cellectis has a consensus rating of “Buy” and a consensus target price of $39.29.
Cellectis (NASDAQ:CLLS) last released its earnings results on Monday, November 13th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.16). Cellectis had a negative net margin of 217.25% and a negative return on equity of 30.66%. analysts forecast that Cellectis will post -2.89 earnings per share for the current fiscal year.
Hedge funds have recently made changes to their positions in the company. Sphera Funds Management LTD. grew its position in shares of Cellectis by 27.6% during the 2nd quarter. Sphera Funds Management LTD. now owns 203,764 shares of the biotechnology company’s stock worth $5,261,000 after buying an additional 44,100 shares during the period. Deltec Asset Management LLC acquired a new stake in shares of Cellectis during the 4th quarter worth approximately $372,000. JPMorgan Chase & Co. acquired a new stake in shares of Cellectis during the 3rd quarter worth approximately $517,000. Balyasny Asset Management LLC acquired a new stake in shares of Cellectis during the 2nd quarter worth approximately $719,000. Finally, Advisors Asset Management Inc. grew its position in shares of Cellectis by 1,501.1% during the 3rd quarter. Advisors Asset Management Inc. now owns 22,592 shares of the biotechnology company’s stock worth $643,000 after buying an additional 21,181 shares during the period. 16.42% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/14/cellectis-clls-downgraded-by-zacks-investment-research-to-sell.html.
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.